Projected Impact of Nonpharmacologic Management of Stage 1 Hypertension Among Lower-Risk US Adults.
Kendra D SimsPengxiao Carol WeiJoanne M PenkoSusan HennessyPamela G CoxsonNita H MukandBrandon K BellowsDhruv S KaziYiyi ZhangRoss BoylanAndrew E MoranKirsten Bibbins-DomingoPublished in: medRxiv : the preprint server for health sciences (2023)
As only two-thirds of U.S. adults with Stage 1 hypertension regularly receive medical care, substantial benefits to cardiovascular health and associated costs may only stem from policies that promote widespread adoption and sustained adherence of nonpharmacologic therapy. Future work should quantify the population-level costs, benefits, and efficacy of improving the food system and local infrastructure on health behavior change.